Modified FOLFOX versus Modified FOLFIRI in Patients with Locally Advanced or Metastatic Biliary Tract Cancer Refractory to First-Line Chemotherapy: A Phase 2 Study

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Results of a phase 2 study indicate that mFOLFIRI was not superior to mFOLFOX in the second-line treatment of patients with biliary tract cancer.

Treatment with second-line chemotherapy is challenging after disease progression from first-line gemcitabine plus cisplatin in patients with locally advanced or metastatic biliary tract cancer. However, treatment with modified FOLFOX (mFOLFOX) was proved to be superior to active symptom control in the ABC-06 trial.1 Irinotecan (Camptosar) is an active drug used in the treatment of various gastrointestinal cancers.

Led by Jin Won Kim, MD, PhD, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, a phase 2 study evaluated whether mFOLFIRI was superior to mFOLFOX in the second-line treatment of patients with biliary tract cancer.2 Study results were presented at this year’s annual meeting of the American Society of Clinical Oncology (ASCO).

Patients diagnosed with biliary tract cancer and had disease progression after receiving gemcitabine plus cisplatin were randomized 1:1 to mFOLFOX or mFOLFIRI. Randomization was stratified by tumor location (intrahepatic vs extrahepatic vs gallbladder vs ampulla of Vater) and Eastern Cooperative Oncology Group (ECOG) performance status (0-2). The primary end point was the overall survival (OS) rate at 6 months.

A total of 120 patients were enrolled in this study, 114 of whom received treatment, including 56 patients who received mFOLFOX and 58 patients who received mFOLFIRI. Patient median age was 63 years. Most (89.5%) patients had ECOG status of 0 or 1. Tumor location was intrahepatic in 47 patients (41.2%), extrahepatic in 27 patients (23.7%), gallbladder in 35 patients (30.7%), and ampulla of Vater in 5 patients (4.4%).

At a median follow-up duration of 25.8 months, the 6-month OS rates were 54.2% and 43.6% in those who received mFOLFOX and those in the mFOLFIRI group, respectively. Of 101 evaluable patients (mFOLFOX, N = 51; mFOLFIRI, N = 50), objective response rates were 5.9% and 66.7% in those with mFOLFOX and with mFOLFIRI, respectively; disease control rates were 4.0% and 64.4% with mFOLFOX and with mFOLFIRI, respectively.

Median progression-free survival rates were 2.8 months and 2.1 months with mFOLFOX and with mFOLFIRI, respectively (P = .887). Median OS rates were 6.3 months and 5.7 months with mFOLFOX and with mFOLFIRI, respectively (P = .472).

The most common grade 3 or 4 adverse events were neutropenia (25.0%) and aspartate transaminase or alanine transaminase elevation (16.1%) in the mFOLFOX group and neutropenia (25.9%) and anemia (17.2%) with the mFOLFIRI group. Peripheral neuropathy (37.5%) and thrombocytopenia (37.5%) occurred more frequently in the mFOLFOX group, and vomiting (19.0%) and cholangitis (10.3%) occurred more frequently with mFOLFIRI. No chemotherapy-related deaths were reported.

The investigators concluded that as second-line therapy for biliary tract cancer, the mFOLFIRI regimen was tolerable but not superior to mFOLFOX.

Source: Kim JW, et al. J Clin Oncol. 2020;38(15_suppl). Abstract 4603.

References

  1. Lamarca A, Palmer DH, Singh Wasan H, et al. ABC-06: a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37(15_suppl):Abstract 4003.
  2. Kim JW, Suh KJ, Kim J-W, et al. A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. J Clin Oncol. 2020;38(15_suppl):Abstract 4603.

Related Items

Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
2022 Year in Review: Cholangiocarcinoma
Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
2022 Year in Review: Cholangiocarcinoma
Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
2022 Year in Review: Cholangiocarcinoma
The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements
2022 Year in Review: Cholangiocarcinoma
Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.
Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?
2022 Year in Review: Cholangiocarcinoma
Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809
2021 Year in Review: Cholangiocarcinoma
Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: